Homology Medicines, Inc. (FIXX): Price and Financial Metrics


Homology Medicines, Inc. (FIXX): $1.97

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FIXX POWR Grades


  • FIXX scores best on the Sentiment dimension, with a Sentiment rank ahead of 68.79% of US stocks.
  • FIXX's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
  • FIXX ranks lowest in Growth; there it ranks in the 9th percentile.

FIXX Stock Summary

  • Of note is the ratio of Homology Medicines Inc's sales and general administrative expense to its total operating expenses; merely 12.83% of US stocks have a lower such ratio.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.18 for Homology Medicines Inc; that's greater than it is for only 12% of US stocks.
  • Revenue growth over the past 12 months for Homology Medicines Inc comes in at 1,157.25%, a number that bests 99.15% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Homology Medicines Inc, a group of peers worth examining would be QURE, VIR, CALA, MTEM, and MRNS.
  • Visit FIXX's SEC page to see the company's official filings. To visit the company's web site, go to www.homologymedicines.com.

FIXX Valuation Summary

  • In comparison to the median Healthcare stock, FIXX's price/earnings ratio is 112.6% lower, now standing at -4.6.
  • Over the past 42 months, FIXX's price/sales ratio has gone NA NA.
  • FIXX's EV/EBIT ratio has moved up 17.3 over the prior 42 months.

Below are key valuation metrics over time for FIXX.

Stock Date P/S P/B P/E EV/EBIT
FIXX 2021-08-31 12.4 1.8 -4.6 -3.4
FIXX 2021-08-30 12.3 1.8 -4.5 -3.4
FIXX 2021-08-27 12.5 1.8 -4.6 -3.4
FIXX 2021-08-26 12.0 1.8 -4.4 -3.3
FIXX 2021-08-25 12.2 1.8 -4.5 -3.3
FIXX 2021-08-24 11.9 1.8 -4.4 -3.2

FIXX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FIXX has a Quality Grade of D, ranking ahead of 17.28% of graded US stocks.
  • FIXX's asset turnover comes in at 0.134 -- ranking 233rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FIXX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.134 1 -1.031
2021-03-31 0.128 1 -1.267
2020-12-31 0.010 1 -1.629
2020-09-30 0.008 1 -0.944
2020-06-30 0.007 1 -0.719
2020-03-31 0.006 1 -0.566

FIXX Price Target

For more insight on analysts targets of FIXX, see our FIXX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.20 Average Broker Recommendation 1.32 (Strong Buy)

FIXX Stock Price Chart Interactive Chart >

Price chart for FIXX

FIXX Price/Volume Stats

Current price $1.97 52-week high $8.90
Prev. close $1.97 52-week low $1.30
Day low $1.86 Volume 124,791
Day high $2.02 Avg. volume 550,340
50-day MA $1.77 Dividend yield N/A
200-day MA $3.88 Market Cap 113.05M

Homology Medicines, Inc. (FIXX) Company Bio


Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.


FIXX Latest News Stream


Event/Time News Detail
Loading, please wait...

FIXX Latest Social Stream


Loading social stream, please wait...

View Full FIXX Social Stream

Latest FIXX News From Around the Web

Below are the latest news stories about Homology Medicines Inc that investors may wish to consider to help them evaluate FIXX as an investment opportunity.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

The Petri Dish: Moderna, Thermo become long-term partners; Karyopharm medical chief departs

The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.

Yahoo | February 24, 2022

Here's Why Homology Medicines (FIXX) is Poised for a Turnaround After Losing 25.1% in 4 Weeks

Homology Medicines (FIXX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | February 23, 2022

Homology Medicines downgraded to perform at Oppenheimer on clinical hold

Oppenheimer has downgraded Homology Medicines (FIXX -26.6%) to perform following the company's announcement on Friday that the U.S. Food and Drug Administration imposed a clinical hold on its pheNIX gene therapy trial of HMI-102 for phenylketonuria. Shares are down ~27%. The firm has also withdrawn its price target. Analyst Matthew Biegler wrote...

Seeking Alpha | February 22, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | February 22, 2022

Read More 'FIXX' Stories Here

FIXX Price Returns

1-mo 34.01%
3-mo -33.89%
6-mo -45.88%
1-year -72.90%
3-year -89.49%
5-year N/A
YTD -45.88%
2021 -67.76%
2020 -45.46%
2019 -7.42%
2018 N/A
2017 N/A

Continue Researching FIXX

Want to see what other sources are saying about Homology Medicines Inc's financials and stock price? Try the links below:

Homology Medicines Inc (FIXX) Stock Price | Nasdaq
Homology Medicines Inc (FIXX) Stock Quote, History and News - Yahoo Finance
Homology Medicines Inc (FIXX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6921 seconds.